Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Myeloma: real-world data

Evangelos Terpos • 15 Jun 2019
EHA 2019
Multiple Myeloma Dexamethasone Ixazomib Lenalidomide
INSIGHT-MM

Evangelos Terpos, MD, PhD, of University of Athens, Athens, Greece discusses how trial data corresponds to the real-world setting with regards to relapsed/refractory myeloma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Evangelos Terpos

2:39
Antibody response to COVID-19 vaccine in patients with multiple myeloma and WM
Evangelos Terpos • 10 Dec 2022
2:02
Ocular AEs observed in patients treated with belantamab mafodotin, lenalidomide & dexamethasone
Evangelos Terpos • 10 Dec 2022
1:14
BelaRd: belantamab mafodotin with lenalidomide and dexamethasone in patients with NDMM
Evangelos Terpos • 10 Dec 2022
3:03
The prognostic impact of circulating plasma cells in patients with multiple myeloma
Evangelos Terpos • 10 Dec 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals